Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280

1.

Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience.

Braun-Moscovici Y, Butbul-Aviel Y, Guralnik L, Toledano K, Markovits D, Rozin A, Nahir MA, Balbir-Gurman A.

Rheumatol Int. 2013 Jun;33(6):1495-504. doi: 10.1007/s00296-012-2587-x. Epub 2012 Dec 14.

PMID:
23239037
2.

Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.

Jovancevic B, Lindholm C, Pullerits R.

Lupus. 2013 Jun;22(7):664-74. doi: 10.1177/0961203313485489. Epub 2013 Apr 23. Review.

PMID:
23612795
3.

Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.

Trachana M, Koutsonikoli A, Farmaki E, Printza N, Tzimouli V, Papachristou F.

Rheumatol Int. 2013 Mar;33(3):809-13. doi: 10.1007/s00296-011-2239-6. Epub 2011 Nov 19.

PMID:
22101555
4.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
5.

Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N.

Arthritis Res Ther. 2013 Sep 24;15(5):R133. doi: 10.1186/ar4313.

6.

Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.

Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, Smith KG, Jayne DR.

Rheumatology (Oxford). 2015 Jul;54(7):1153-60. doi: 10.1093/rheumatology/keu452. Epub 2014 Dec 3.

7.

Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D.

Rheumatology (Oxford). 2006 Nov;45(11):1432-6. Epub 2006 Apr 21.

PMID:
16632482
8.

Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.

Can M, Alibaz-Öner F, Yılmaz-Öner S, Atagündüz P, İnanç N, Direskeneli H.

Clin Rheumatol. 2013 Jan;32(1):87-90. doi: 10.1007/s10067-012-2094-1. Epub 2012 Oct 11.

PMID:
23053686
9.

B cell depletion for autoimmune diseases in paediatric patients.

Jansson AF, Sengler C, Kuemmerle-Deschner J, Gruhn B, Kranz AB, Lehmann H, Kleinert D, Pape L, Girschick HJ, Foeldvari I, Haffner D, Haas JP, Moebius D, Foell D, Peitz J, Grote V.

Clin Rheumatol. 2011 Jan;30(1):87-97. doi: 10.1007/s10067-010-1630-0. Epub 2010 Dec 1.

PMID:
21120559
10.

Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab).

Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K.

Rheumatology (Oxford). 2011 Aug;50(8):1390-4. doi: 10.1093/rheumatology/ker107. Epub 2011 Mar 4.

PMID:
21378109
11.

Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?

Galarza C, Valencia D, Tobón GJ, Zurita L, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Rueda JC, Anaya JM.

Clin Rev Allergy Immunol. 2008 Feb;34(1):124-8. doi: 10.1007/s12016-007-8028-z.

PMID:
18270866
12.
13.

Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence.

Narváez J, Ríos-Rodriguez V, de la Fuente D, Estrada P, López-Vives L, Gómez-Vaquero C, Nolla JM.

Semin Arthritis Rheum. 2011 Dec;41(3):364-72. doi: 10.1016/j.semarthrit.2011.06.004. Epub 2011 Aug 27.

PMID:
21875742
14.

A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.

De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G.

Arthritis Rheum. 2012 Mar;64(3):843-53. doi: 10.1002/art.34331.

15.

Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry.

Puéchal X, Gottenberg JE, Berthelot JM, Gossec L, Meyer O, Morel J, Wendling D, de Bandt M, Houvenagel E, Jamard B, Lequerré T, Morel G, Richette P, Sellam J, Guillevin L, Mariette X; Investigators of the AutoImmunity Rituximab Registry..

Arthritis Care Res (Hoboken). 2012 Mar;64(3):331-9. doi: 10.1002/acr.20689.

16.

Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.

Conti F, Ceccarelli F, Perricone C, Alessandri C, Conti V, Massaro L, Truglia S, Spinelli FR, Spadaro A, Valesini G.

Rheumatology (Oxford). 2011 Jun;50(6):1148-52. doi: 10.1093/rheumatology/keq436. Epub 2011 Jan 28.

PMID:
21278072
17.

[B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].

Tanaka Y.

Yakugaku Zasshi. 2009 Jun;129(6):675-9. Review. Japanese.

18.

Pediatric systemic lupus erythematosus in Thammasat University Hospital.

Pusongchai T, Jungthirapanich J, Khositseth S.

J Med Assoc Thai. 2010 Dec;93 Suppl 7:S283-93.

PMID:
21294427
19.

Rituximab for noninfectious uveitis.

Miserocchi E, Modorati G.

Dev Ophthalmol. 2012;51:98-109. doi: 10.1159/000336188. Epub 2012 Apr 17. Review.

PMID:
22517208
20.

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Finckh A, Ciurea A, Brulhart L, Möller B, Walker UA, Courvoisier D, Kyburz D, Dudler J, Gabay C; Arthritis..

Ann Rheum Dis. 2010 Feb;69(2):387-93. doi: 10.1136/ard.2008.105064. Epub 2009 May 4.

Supplemental Content

Support Center